GZS-411ГЗС-411
What is it?
A 2026 experimental dimeric dipeptide designed from NT-4 loop 1. Its currently linked findings are cell-based.
Research context
A 2026 experimental dimeric dipeptide designed from NT-4 loop 1. Its currently linked findings are cell-based.
What the studies found
in vitro · 2026
Mouse HT-22 and human SH-SY5Y cell lines
GZS-411 activated TrkB and protected cultured cells against oxidative stress, glutamate toxicity and 6-hydroxydopamine. The study does not establish animal or human treatment effects.
Limit: Preclinical findings do not establish human benefit or safety.
N-Isocaproyl-L-Arginylglycine Hexamethylenediamide, First Low-Molecular-Weight Mimetic of Neurotrophin-4: Design and Neuroprotective Activity. ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Experimental peptide
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
The research record
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| GZS-411 | NT-4 loop 1 mimetic | TrkB activation and protection in HT-22 and SH-SY5Y injury assays. |
Interpretation and open questions
Human-derived SH-SY5Y cells are not human participants. No human efficacy inference is made.
An additional GZS-4xx analogue library is not established by the located source.
Linked sources
Explore the research map and unresolved leads ↗
N-Isocaproyl-L-Arginylglycine Hexamethylenediamide, First Low-Molecular-Weight Mimetic of Neurotrophin-4: Design and Neuroprotective Activity.
Gudasheva TA, Sokolenko NI, Kolyasnikova KN, Antipova TA, Zainullina LF, Sergeeva MS, Dorofeev VL · Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
GZS-411 activated TrkB and protected cultured cells against oxidative stress, glutamate toxicity and 6-hydroxydopamine. The study does not establish animal or human treatment effects.
- Population / setting
- Mouse HT-22 and human SH-SY5Y cell lines
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.